translocations or amplifications along with the genomic alterations now present in the first CLL, but absence the frequent mutations observed in Principal DLBCL indicating that they could correspond to a special Organic class.Unfit individuals also have the alternative of venetoclax plus obinutuzumab (VO) as frontline therapy. This is based with a